Literature DB >> 16636527

Comparison of clinical characteristics and outcomes of patients with COPD exacerbation with or without venous thromboembolism.

Metin Akgun1, Mehmet Meral, Omer Onbas, Omer Araz, Mustafa Koplay, Sahin Aslan, Arzu Mirici.   

Abstract

BACKGROUND: Although some studies evaluated venous thromboembolism (VTE) prevalence in patients with chronic obstructive pulmonary disease (COPD), they contain no detailed description of the patients' characteristics.
OBJECTIVES: It was the aim of this study to investigate the frequency and clinical characteristics and outcomes of VTE in patients with COPD exacerbation.
METHODS: Between October 2004 and February 2005, 120 consecutive patients were included in the study. On admission, Doppler examination of lower extremities in all cases and spiral computed tomography of the thorax in cases with a suspicion of pulmonary thromboembolism were performed. A questionnaire was used to take a detailed history. In addition to routine laboratory tests, chest X-ray, postbronchodilator spirometry, arterial blood gas analysis and serum levels of D-dimer and C-reactive protein were evaluated, as well as dyspnea score and performance status before exacerbation. The hospitalization durations and mechanical ventilation requirements were also recorded.
RESULTS: VTE was determined in 16 cases (13.3%). In patients with VTE, the travel history was higher (p < 0.001), the dyspnea score worse (p = 0.005), the duration of hospitalization longer (p < 0.001) and the mechanical ventilation requirement increased (p < 0.001); a change in mental status was highly associated with the presence of VTE (p < 0.001).
CONCLUSIONS: It seems that VTE occurrence was higher in the presence of a risk factor causing immobility such as travel history and increased dyspnea. The cases with severe disease are more likely to have VTE. Preventive measures may be considered in such patients because their hospitalization stay and mechanical ventilation requirement are increased.

Entities:  

Mesh:

Year:  2006        PMID: 16636527     DOI: 10.1159/000092952

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Should the cut-off value of D-dimer be elevated to exclude pulmonary embolism in acute exacerbation of COPD?

Authors:  Evrim Eylem Akpinar; Derya Hoşgün; Beyza Doğanay; Gökçe Kaan Ataç; Meral Gülhan
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Risk Factors for Venous Thromboembolism in Chronic Obstructive Pulmonary Disease.

Authors:  Victor Kim; Nishant Goel; Jinal Gangar; Huaqing Zhao; David E Ciccolella; Edwin K Silverman; James D Crapo; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2014

3.  Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study.

Authors:  Elif Küpeli; Gaye Ulubay; Sevinc Sarinc Ulasli; Tugce Sahin; Zeynep Erayman; Alptekin Gürsoy
Journal:  Endocrine       Date:  2010-06-09       Impact factor: 3.633

4.  Venous thromboembolism in patients with chronic obstructive pulmonary disease.

Authors:  Gregory Piazza; Samuel Z Goldhaber; Aimee Kroll; Robert J Goldberg; Catherine Emery; Frederick A Spencer
Journal:  Am J Med       Date:  2012-08-08       Impact factor: 4.965

5.  Diagnostic Value of D-dimer in Detecting Pulmonary Embolism in Patients with Acute COPD Exacerbation.

Authors:  Somayeh Sadeghi; Mohammad Emami Ardestani; Elham Raofi; Akbar Jalaie Esfandabadi
Journal:  Tanaffos       Date:  2020-12

6.  Prevalence of Pulmonary Embolism and Deep Venous Thromboembolism in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Authors:  Weihong Han; Minghang Wang; Yang Xie; Huanrong Ruan; Hulei Zhao; Jiansheng Li
Journal:  Front Cardiovasc Med       Date:  2022-03-09

Review 7.  Pulmonary Embolism in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Yao-Qian Cao; Li-Xia Dong; Jie Cao
Journal:  Chin Med J (Engl)       Date:  2018-07-20       Impact factor: 2.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.